Control of Toxocara canis in puppies: a comparison of screening techniques and evaluation of a dosing programme.
Conventional chemoprophylaxis of canine toxocariasis is based upon the treatment of young puppies. It is proposed that physiological considerations and the complexity of the host-parasite relationship in the case of Toxocara canis demand that anthelmintic evaluation should properly be conducted in such animals rather than in adolescent or adult dogs. A screening model using the critical trial technique in early weaned pups gave variable results even with compounds known to be of high efficacy in older dogs. Circumstantial evidence suggested that this inconsistency may be related to the rate of passage of ingesta through such young animals. More satisfactory results were obtained by pairing unweaned naturally infected puppies by weight and sex and treating one of each pair with the test compound. Natural in utero and transmammary infection was found to give fairly consistent worm-burdens within each litter and a good indication of efficacy could therefore be estimated by comparing post mortem worm-counts. On this basis, the apparent efficacies of pyrantel pamoate (5 mg kg-1) and piperazine (100 mg kg-1) were found to be 83.5 and 82.5%, respectively. This method was extended to evaluate a prophylactic programme in which anthelmintic therapy was given to pups when aged 10, 20 and 30 days. Intestinal T. canis populations were reduced, at 35 days of age, by between 94.2% and 98.0%. This programme increased overall weight gains between 10 and 30 days of age by 18% (P less than 0.05) although there was great variation between litters. The biggest response was observed in male pups between 20 and 30 days old.
D000818:Animals; D000833:Animals, Suckling / Q000469:parasitology; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D001196:Ascariasis / Q000662:veterinary*; D001835:Body Weight; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004334:Drug Administration Schedule; D005243:Feces / Q000469:parasitology; D005260:Female; D008297:Male; D010270:Parasite Egg Count; D010647:Phenyl Ethers / Q000008:administration & dosage / Q000627:therapeutic use; D000077489:Piperazine; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011715:Pyrantel / Q000031:analogs & derivatives*; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*; D013861:Thiocyanates / Q000008:administration & dosage / Q000627:therapeutic use; D014120:Toxocariasis / Q000188:drug therapy / Q000662:veterinary*
D000871:Anthelmintics; D010647:Phenyl Ethers; D010879:Piperazines; D013861:Thiocyanates; D000077489:Piperazine; D011715:Pyrantel; D011716:Pyrantel Pamoate; C011042:nitroscanate